TRI-611

TRI-611 is a protein degrader developed by TRIANA Biomedicines. Its target is ALK (the sponsor names ALK). The sponsor states: TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07491497, plans to enrol 160 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.